【醫藥護人員場】5. Enzalutamide (Xtandi, 安可坦) | 臺大泌尿部/臺灣楓城泌尿學會

00:00 1.
台灣長庚紀念醫院
01:00 2.
Enzalutamide vs Current Antiandrogen Agents
01:41 3.
Non-steroidal antiandrogens
02:03 4.
Mechanism of action of AR antagonists
02:41 5.
MDV3100: Second generation antiandrogen
03:11 6.
Enzalutamide Suppress PSA Level
03:23 7.
Slide 7
04:00 8.
Survival analysis
04:24 9.
Secondary End Points Analaysis
05:00 10.
Hazard Ratios for Death
05:26 11.
Adverse Events
06:36 12.
Slide 12
07:21 13.
Survival analysis
07:36 14.
Time Until Initiation of Chemotherapy and Rising of PSA Level
08:00 15.
Secondary End Points Analaysis
08:37 16.
Adverse Events
08:57 17.
Slide 17
09:29 18.
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
10:21 19.
Slide 19
10:39 20.
Adverse Effects and Conclusions
11:23 21.
Slide 21
11:36 22.
Slide 22
11:41 23.
Slide 21
11:45 24.
Slide 22
11:56 25.
Slide 23
12:11 26.
Slide 24
13:01 27.
Slide 25
13:18 28.
Slide 26
13:24 29.
Conclusions

未登入或權限不足!

講者：馮思中

日期：2016-05-10

觀看: 2282

00:00 1.
台灣長庚紀念醫院
01:00 2.
Enzalutamide vs Current Antiandrogen Agents
01:41 3.
Non-steroidal antiandrogens
02:03 4.
Mechanism of action of AR antagonists
02:41 5.
MDV3100: Second generation antiandrogen
03:11 6.
Enzalutamide Suppress PSA Level
03:23 7.
Slide 7
04:00 8.
Survival analysis
04:24 9.
Secondary End Points Analaysis
05:00 10.
Hazard Ratios for Death
05:26 11.
Adverse Events
06:36 12.
Slide 12
07:21 13.
Survival analysis
07:36 14.
Time Until Initiation of Chemotherapy and Rising of PSA Level
08:00 15.
Secondary End Points Analaysis
08:37 16.
Adverse Events
08:57 17.
Slide 17
09:29 18.
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
10:21 19.
Slide 19
10:39 20.
Adverse Effects and Conclusions
11:23 21.
Slide 21
11:36 22.
Slide 22
11:41 23.
Slide 21
11:45 24.
Slide 22
11:56 25.
Slide 23
12:11 26.
Slide 24
13:01 27.
Slide 25
13:18 28.
Slide 26
13:24 29.
Conclusions

【醫藥護人員場】5. Enzalutamide (Xtandi, 安可坦)

長度: 14:24, 瀏覽: 2283, 最近修訂: 2017-05-09

演講時間：9:10-10:10

講者：馮思中教授

現任職位/稱：

林口長庚醫院泌尿科系教授

瑞典 Karolinska Institute 醫學博士

台灣泌尿腫瘤醫學會理事

00:00 1.
台灣長庚紀念醫院
01:00 2.
Enzalutamide vs Current Antiandrogen Agents
01:41 3.
Non-steroidal antiandrogens
02:03 4.
Mechanism of action of AR antagonists
02:41 5.
MDV3100: Second generation antiandrogen
03:11 6.
Enzalutamide Suppress PSA Level
03:23 7.
Slide 7
04:00 8.
Survival analysis
04:24 9.
Secondary End Points Analaysis
05:00 10.
Hazard Ratios for Death
05:26 11.
Adverse Events
06:36 12.
Slide 12
07:21 13.
Survival analysis
07:36 14.
Time Until Initiation of Chemotherapy and Rising of PSA Level
08:00 15.
Secondary End Points Analaysis
08:37 16.
Adverse Events
08:57 17.
Slide 17
09:29 18.
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
10:21 19.
Slide 19
10:39 20.
Adverse Effects and Conclusions
11:23 21.
Slide 21
11:36 22.
Slide 22
11:41 23.
Slide 21
11:45 24.
Slide 22
11:56 25.
Slide 23
12:11 26.
Slide 24
13:01 27.
Slide 25
13:18 28.
Slide 26
13:24 29.
Conclusions

位置

資料夾名稱

2016臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2016-05-10 12:27:00

最近修訂

2017-05-09 09:59:57

長度

14:24